Literature DB >> 14734014

Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor beta.

Jasmin Bektic1, Andreas P Berger, Karina Pfeil, Gabriele Dobler, Georg Bartsch, Helmut Klocker.   

Abstract

OBJECTIVES: Isoflavonoids are discussed for use in chemoprevention and treatment of prostate cancer. We investigated the potential of genistein to modulate androgen receptor (AR) expression and transcriptional activity in the human androgen-sensitive prostate cancer cell line LNCaP.
MATERIALS AND METHODS: AR expression at mRNA and protein level was analyzed by real-time RT-PCR and immunoblot, respectively. In conditioned media PSA was measured by a microparticle enzyme immunoassay (MEIA). Binding of genistein to the AR was tested in a radioligand-binding assay and reporter gene co-transfection assay was employed to investigate AR activity.
RESULTS: Using concentrations of genistein that have been detected in sera of Asian men on regular soy-diet we found down-regulation of androgen receptor at both mRNA and protein level. The relative binding affinity to the AR was below 4% when compared to methyltrienologe (R1881) and there was no modulation of AR transcriptional activity by genistein concentrations up to 1 microM. We also demonstrated inhibition of PSA secretion after genistein treatment. As the anti-estrogen ICI 164 384 abolished the inhibitory effect of genistein and ER-beta, but not ER-alpha is expressed in LNCaP cells we postulate that the mechanism of genistein action on androgen receptor is mediated through ER-beta.
CONCLUSION: Using physiological concentrations of genistein we showed AR down-regulation by genistein in prostate cancer cells occurring via ER-beta. This likely results in a modified response to hormonal stimuli and may help to explain the low incidence of prostate cancer in the Asian population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14734014     DOI: 10.1016/j.eururo.2003.09.001

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  24 in total

1.  Effects of selenite and genistein on G2/M cell cycle arrest and apoptosis in human prostate cancer cells.

Authors:  Rui Zhao; Nong Xiang; Fredrick E Domann; Weixiong Zhong
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

2.  Genistein increases estrogen receptor beta expression in prostate cancer via reducing its promoter methylation.

Authors:  Abeer M Mahmoud; Umaima Al-Alem; Mohamed M Ali; Maarten C Bosland
Journal:  J Steroid Biochem Mol Biol       Date:  2015-04-27       Impact factor: 4.292

3.  Expression of estrogen receptor alpha and beta is decreased in hypospadias.

Authors:  Liang Qiao; Esequiel Rodriguez; Dana A Weiss; Max Ferretti; Gail Risbridger; Gerald R Cunha; Laurence S Baskin
Journal:  J Urol       Date:  2012-02-16       Impact factor: 7.450

4.  Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies.

Authors:  Sabine Schertl; Rolf W Hartmann; Christine Batzl-Hartmann; Thilo Spruss; Anton Maucher; Erwin von Angerer; Claus D Schiller; Martin R Schneider; Ronald Gust; Helmut Schönenberger
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-06       Impact factor: 4.553

5.  Combination of calcitriol and dietary soy exhibits enhanced anticancer activity and increased hypercalcemic toxicity in a mouse xenograft model of prostate cancer.

Authors:  Jennifer Y Wang; Srilatha Swami; Aruna V Krishnan; David Feldman
Journal:  Prostate       Date:  2012-03-27       Impact factor: 4.104

6.  Prostatic soy isoflavone concentrations exceed serum levels after dietary supplementation.

Authors:  Christopher D Gardner; Beibei Oelrich; Jenny P Liu; David Feldman; Adrian A Franke; James D Brooks
Journal:  Prostate       Date:  2009-05-15       Impact factor: 4.104

7.  Pharmacological exploitation of the peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents.

Authors:  Jian Yang; Shuo Wei; Da-Sheng Wang; Yu-Chieh Wang; Samuel K Kulp; Ching-Shih Chen
Journal:  J Med Chem       Date:  2008-03-13       Impact factor: 7.446

Review 8.  [A critical assessment of phytotherapy for prostate cancer].

Authors:  F G E Perabo; E C von Löw; R Siener; J Ellinger; S C Müller; P J Bastian
Journal:  Urologe A       Date:  2009-03       Impact factor: 0.639

9.  3,3'-Diindolylmethane and genistein decrease the adverse effects of estrogen in LNCaP and PC-3 prostate cancer cells.

Authors:  Sunyata Smith; Daniel Sepkovic; H Leon Bradlow; Karen J Auborn
Journal:  J Nutr       Date:  2008-12       Impact factor: 4.798

Review 10.  Soy isoflavones and prostate cancer: a review of molecular mechanisms.

Authors:  Abeer M Mahmoud; Wancai Yang; Maarten C Bosland
Journal:  J Steroid Biochem Mol Biol       Date:  2013-12-25       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.